Decoding the Human Element for Analytics Success

Posted by Arnab Roy on May 30, 2019

Maria Kliatchko and Indraneel Mukherjee co-wrote this blog post with Arnab Roy. This blog post is the second in a two-part series on how medtech companies can find success with analytics.

Everyone loves the idea of analytics making their lives easier, but in practice medtech companies don’t always realize the broader goals of their analytics programs. Even when analytics initiatives are well planned and executed, they often fail to yield their expected returns due to one factor that often slips under the radar: the human element.


>
Read More

What It Takes for Multinational Medtech Companies to Succeed in China

Posted by ZS Editors on April 9, 2019

With a population of 1.4 billion, China is a market that most medtech companies can’t afford to ignore. However, differences in population types (urban versus rural), the government’s role in healthcare expansion and a multi-tiered distribution system that is undergoing reform make navigating the Chinese market a challenge.


>
Read More

Thanks for the ‘Ones’ and ‘Zeros,’ Dr. Gottlieb

Posted by Brian Chapman on March 15, 2019

I admit, the title of this post is an attempt at a ham-fisted connection between the FDA’s impressive, forward-looking digital strategy under Commissioner Scott Gottlieb (as he wraps up his post following his March 5th resignation) and an overall reckoning from his tenure. I also must admit that my assessment has some shortcomings: I watch the FDA from a distance, avoid the political elements and focus only on the medtech industry (drug prices, generic approvals and vaping notwithstanding). Although Jeffrey Shuren, the director of the Center for Devices and Radiological Health, and others at the FDA probably should share credit for many of the positive accomplishments in medtech, the tenure of a leader should be judged by the organization’s accomplishments during that time. As Gottlieb prepares to move on from his role in public service, I’d like to share a few thoughts on the agency’s recent impact on the medtech industry.


>
Read More

Into 2019: Risk, Uncertainty and a Return to Product Focus

Posted by Brian Chapman on January 23, 2019

Looking ahead to what the medtech industry can expect in 2019, I see a continuation of some of the greatest accomplishments of 2018, such as ongoing collaboration with regulatory bodies and real-world evidence driving more reimbursement discussions, as well as the brave new world of digital health continuing to buoy how our industry can help patients.


>
Read More

Ushering in 2019: Medtech’s Year to Come

Posted by Tobi Laczkowski on January 17, 2019

A new year has come, so it’s time to take a step back and make some observations about the industry’s 2018 evolution and provide some thoughts on how 2019 is shaping up.


>
Read More